JETIREXPLORE- Search Thousands of research papers



Published in:

Volume 5 Issue 1
January-2018
eISSN: 2349-5162

Unique Identifier

JETIR1801090

Page Number

467-472

Share This Article


Title

Resistant Anti-Malarial drugs in Plasmodium Falciparum and the current strategies to overcome them

ISSN

2349-5162

Cite This Article

"Resistant Anti-Malarial drugs in Plasmodium Falciparum and the current strategies to overcome them", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.5, Issue 1, page no.467-472, January-2018, Available :http://www.jetir.org/papers/JETIR1801090.pdf

Abstract

The main objective of this thesis was to study the nasal administration of Azithromycin and Chloroquine, effective in the treatment Antimalerial –Antibiotics pregnancy. A fixed-dose combination of azithromycin and chloroquine (AZCQ) is in development for intermittent preventive treatment of malaria in pregnant women (IPTp). The combination has demonstrated synergistic activity against chloroquine resistant strains of Plasmodium falciparum in vitro and in vivo and efficacy in Phase 2 and 3 treatment studies in patients with symptomatic uncomplicated P. falciparum malaria. This was an open-label, randomized, single-dose, parallel-group study to estimate the relative bioavailability of two AZCQ tablets, each containing azithromycin base 250 mg and chloroquine base 155 mg (test treatment), compared with the coadministration of commercially available individual tablets of azithromycin base 500 mg and chloroquine base 300 mg (reference treatment). There is a strong rationale for developing AZCQ for IPTp. First, the combination of AZ and CQ has demonstrated synergistic activity against CQ-resistant strains of Plasmodium falciparum in vitro and in vivo . Co-administration of AZ and CQ has demonstrated over 95% efficacy in Phase 2 and 3 clinical trials in India. The relative bioavailability as measured by AUClast ratio of adjusted geometric means (90% confidence interval) for the two AZCQ tablets was 101% (85.4%, 119%) for azithromycin and 99.1% (84.0%, 117%) for chloroquine compared with the reference treatment. Maximum concentration values for the two AZCQ tablets were approximately 13.0% higher for azithromycin and 11.0% lower for chloroquine compared with reference treatment. Both treatments were well tolerated. This AZCQ tablet formulation is currently being evaluated in Phase 3 clinical trials for IPTp.

Key Words

Falciparum malaria, azithromycin, chloroquine and reference treatment etc.,

Cite This Article

"Resistant Anti-Malarial drugs in Plasmodium Falciparum and the current strategies to overcome them", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.5, Issue 1, page no. pp467-472, January-2018, Available at : http://www.jetir.org/papers/JETIR1801090.pdf

Publication Details

Published Paper ID: JETIR1801090
Registration ID: 171168
Published In: Volume 5 | Issue 1 | Year January-2018
DOI (Digital Object Identifier):
Page No: 467-472
ISSN Number: 2349-5162

Download Paper

Preview Article

Download Paper




Cite This Article

"Resistant Anti-Malarial drugs in Plasmodium Falciparum and the current strategies to overcome them", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.5, Issue 1, page no. pp467-472, January-2018, Available at : http://www.jetir.org/papers/JETIR1801090.pdf




Preview This Article


Downlaod

Click here for Article Preview